Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Compliance Certificate - Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Period 1St October, 2016 To 31St March, 2017

 As per the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that all activities in relation to both physical and electronic share transfer facility during the period October 1, 2016 to March 31, 2017 (both days inclusive) are maintained by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share...
11-04-2017
Bigul

Updates

 As required under Regulation 33(3)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company will additionally be submitting quarterly/year to date Consolidated financial results along with Standalone financial results during the financial year 2017-2018.
10-04-2017
Bigul

Sun Pharma slips 3% after US FDA visit at Dadra plant

 Dadra is firm's second most important plant serving US market, contributes $250 mn; Stock dips 3%
08-04-2017
Bigul

Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Pvt Ltd
07-04-2017
Bigul

Sun Pharma, Cadila Healthcare recall products from US market

 The nationwide ongoing voluntary recall by the firm is a class II recall.
30-03-2017
Bigul

Sun Pharma looks to shine with tiny deals

 Mumbai, 27 MarchSun Pharmaceutical's subsidiary, Taro, made a tiny acquisition of Thallion Pharmaceuticals for $1.7 million in Canada on March 17. It was the ninth acquisition by Sun Pharma and its subsidiaries in the previous two years since it made a $4.2-billion big-bang acquisition of Ranbaxy Laboratories in 2015.Till the acquisition of Ranbaxy, the company had made only seven acquisition in 18 years, including Taro Pharma in Israel in 2010. The first was in 1997, when it acquired US-based Caraco for $37.5 million. This gave the Dilip Shanghvi-promoted company an entry into the lucrative US markets."With the Ranbaxy acquisition, Sun Pharma got a wide marketing platform," says Ajay Garg, managing director, Equirus Capital, a home-grown investment banking firm advising on pharma mergers and acquisitions. "Following this, they have adopted a string of pearls strategy by largely acquiring specialty product companies which they can milk well across the marketing platform."Thallion...
28-03-2017
Bigul

Sun Pharma's partner Almirall applies for psoriasis drug approval in Europe

 Two firms had entered into a licensing agreement for investigational drug tildrakizumab in July 2016
24-03-2017
Bigul

Press Release

 Dear Sirs, We are pleased to enclose herewith our Press Release relating to Regulatory Filing of Tildrakizumab in Europe, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,
24-03-2017
Bigul

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha S Valia
24-03-2017
Bigul

Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanghvi Finance Private Limited
23-03-2017
Next Page
Close

Let's Open Free Demat Account